“…Additionally, with the advent of recombinant single-domain antibodies (termed nanobodies), which are now routinely used in both research and clinical applications, interest in using camelid species for antibody production has climbed sharply (Hamers-Casterman et al, 1993; Harmsen and De Haard, 2007; Muyldermans, 2013; Fridy et al, 2014; Klarenbeek et al, 2015). While large domestic animals are crucial for these reasons, their use is often prohibitive due to the high cost associated with using them, the facilities necessary to house them, and the ethical issues associated with experimentation on large mammals (Hanly et al, 1995; Wilde et al, 1996; Hein and Griebel, 2003; Conti et al, 2014). …”